E
Ethan B. Russo
Researcher at GW Pharmaceuticals
Publications - 50
Citations - 5789
Ethan B. Russo is an academic researcher from GW Pharmaceuticals. The author has contributed to research in topics: Cannabis & Cannabinoid. The author has an hindex of 26, co-authored 48 publications receiving 4661 citations. Previous affiliations of Ethan B. Russo include University of Montana & Salisbury University.
Papers
More filters
Journal ArticleDOI
Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects
TL;DR: Particular focus will be placed on phytocannabinoid‐terpenoid interactions that could produce synergy with respect to treatment of pain, inflammation, depression, anxiety, addiction, epilepsy, cancer, fungal and bacterial infections (including methicillin‐resistant Staphylococcus aureus).
Journal ArticleDOI
Agonistic Properties of Cannabidiol at 5-HT1a Receptors
TL;DR: These studies demonstrate that CBD is a modest affinity agonist at the human 5-HT1a receptor, and indicate that cannabidiol may have interesting and useful potential beyond the realm of cannabinoid receptors.
Journal ArticleDOI
A tale of two cannabinoids : The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol
Ethan B. Russo,Geoffrey Guy +1 more
TL;DR: The hypothesis that the combination of THC and CBD increases clinical efficacy while reducing adverse events is supported, and prospects for future application of whole cannabis extracts in neuroprotection, drug dependency, and neoplastic disorders are examined.
Journal ArticleDOI
History of Cannabis and Its Preparations in Saga, Science, and Sobriquet
TL;DR: This most versatile botanical has provided a mirror to medicine and has pointed the way in the last two decades toward a host of medical challenges from analgesia to weight loss through the discovery of its myriad biochemical attributes and the endocannabinoid system wherein many of its components operate.
Journal ArticleDOI
Practical considerations in medical cannabis administration and dosing
TL;DR: Suggestions are offered on cannabis-drug interactions, patient monitoring, and standards of care, while special cases for cannabis therapeutics are addressed: epilepsy, cancer palliation and primary treatment, chronic pain, use in the elderly, Parkinson disease, paediatrics, with concomitant opioids, and in relation to driving and hazardous activities.